Descriptor English: | Cytarabine | ||||||
Descriptor Spanish: |
Citarabina
| ||||||
Descriptor Portuguese: | Citarabina | ||||||
Descriptor French: | Cytarabine | ||||||
Entry term(s): |
Ara C Ara-C Arabinofuranosylcytosine Arabinoside, Cytosine Arabinosylcytosine Aracytidine Aracytine Cytarabine Hydrochloride Cytonal Cytosar Cytosar U Cytosar-U Cytosine Arabinoside beta Ara C beta-Ara C |
||||||
Tree number(s): |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D003561 | ||||||
Scope note: | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Antimetabolites, Antineoplastic Antiviral Agents Immunosuppressive Agents |
||||||
Registry Number: | 04079A1RDZ | ||||||
CAS Type 1 Name: | 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl- | ||||||
Public MeSH Note: | 1966 |
||||||
History Note: | 1966 |
||||||
Related: |
Decitabine
MeSH | ||||||
DeCS ID: | 3578 | ||||||
Unique ID: | D003561 | ||||||
NLM Classification: | QV 269 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1966/01/01 | ||||||
Date of Entry: | 1999/01/01 | ||||||
Revision Date: | 2018/02/28 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Cytarabine
- Preferred
beta-Ara C
- Narrower
Cytarabine Hydrochloride
- Narrower
Cytosar
- Narrower
Ara-C
- Narrower
Aracytine
- Narrower
Cytonal
- Narrower
Concept UI |
M0005564 |
Scope note | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) |
Preferred term | Cytarabine |
Entry term(s) |
Arabinofuranosylcytosine Arabinoside, Cytosine Arabinosylcytosine Aracytidine Cytosine Arabinoside |
Concept UI |
M0369308 |
Preferred term | beta-Ara C |
Entry term(s) |
beta Ara C |
Concept UI |
M0005565 |
Preferred term | Cytarabine Hydrochloride |
Concept UI |
M0005566 |
Preferred term | Cytosar |
Entry term(s) |
Cytosar U Cytosar-U |
Concept UI |
M0369310 |
Preferred term | Ara-C |
Entry term(s) |
Ara C |
Concept UI |
M0369309 |
Preferred term | Aracytine |
Concept UI |
M0372750 |
Preferred term | Cytonal |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey